Tower Research Capital (TRC)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,633
| Closed | -$167K | – | 6393 |
|
|
2023
Q2 | $167K | Buy |
1,633
+873
| +115% | +$82.6K | 0.01% | 1689 |
|
|
2023
Q1 | $69K | Buy |
760
+327
| +76% | +$19.2K | ﹤0.01% | 2218 |
|
|
2022
Q4 | $16K | Sell |
433
-2,448
| -85% | -$84.2K | ﹤0.01% | 3392 |
|
|
2022
Q3 | $72K | Buy |
2,881
+1,840
| +177% | +$51K | ﹤0.01% | 2855 |
|
|
2022
Q2 | $32K | Sell |
1,041
-8,635
| -89% | -$258K | ﹤0.01% | 3317 |
|
|
2022
Q1 | $317K | Buy |
9,676
+7,283
| +304% | +$216K | ﹤0.01% | 1444 |
|
|
2021
Q4 | $63K | Buy |
2,393
+1,974
| +471% | +$153K | ﹤0.01% | 2586 |
|
|
2021
Q3 | $42K | Sell |
419
-892
| -68% | -$105K | ﹤0.01% | 3103 |
|
|
2021
Q2 | $185K | Buy |
1,311
+749
| +133% | +$84.6K | ﹤0.01% | 1987 |
|
|
2021
Q1 | $56K | Buy |
562
+13
| +2% | +$1.52K | ﹤0.01% | 3038 |
|
|
2020
Q4 | $68K | Sell |
549
-572
| -51% | -$75.2K | ﹤0.01% | 2770 |
|
|
2020
Q3 | $109K | Sell |
1,121
-2,815
| -72% | -$352K | ﹤0.01% | 3094 |
|
|
2020
Q2 | $614K | Buy |
3,936
+1,319
| +50% | +$201K | 0.03% | 840 |
|
|
2020
Q1 | $378K | Buy |
+2,617
| New | +$505K | 0.02% | 529 |
|
|
2019
Q4 | – | Sell |
-545
| Closed | -$44K | – | 4605 |
|
|
2019
Q3 | $44K | Buy |
545
+513
| +1,603% | +$43.5K | ﹤0.01% | 1900 |
|
|
2019
Q2 | $3K | Buy |
+32
| New | +$2.76K | ﹤0.01% | 3186 |
|
|
2019
Q1 | – | Sell |
-102
| Closed | -$6K | – | 4453 |
|
|
2018
Q4 | $6K | Sell |
102
-1,296
| -93% | -$79.1K | ﹤0.01% | 2833 |
|
|
2018
Q3 | $114K | Buy |
1,398
+1,027
| +277% | +$72.4K | 0.01% | 1272 |
|
|
2018
Q2 | $13K | Buy |
+371
| New | +$11.3K | ﹤0.01% | 2679 |
|
|
2018
Q1 | – | Sell |
-2,771
| Closed | -$78K | – | 4001 |
|
|
2017
Q4 | $78K | Buy |
2,771
+1,440
| +108% | +$40.2K | 0.01% | 1029 |
|
|
2017
Q3 | $41K | Buy |
+1,331
| New | +$40K | ﹤0.01% | 2158 |
|
|
2017
Q2 | – | Sell |
-155
| Closed | -$4K | – | 3629 |
|
|
2017
Q1 | $4K | Sell |
155
-407
| -72% | -$10.1K | ﹤0.01% | 2374 |
|
|
2016
Q4 | $12K | Buy |
562
+462
| +462% | +$11.7K | ﹤0.01% | 2555 |
|
|
2016
Q3 | $3K | Sell |
100
-332
| -77% | -$6.59K | ﹤0.01% | 2930 |
|
|
2016
Q2 | $8K | Buy |
+432
| New | +$8.4K | ﹤0.01% | 3053 |
|
Other funds holding RETA
Tower Research Capital (TRC)'s RETA Position: Q3 2023 in Review
Tower Research Capital (TRC) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,633 shares — an estimated $167K sold.
Tower Research Capital (TRC) first reported a position in RETA in Q2 2016 and held it in 25 quarters. The position peaked at $614K in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Tower Research Capital (TRC) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,633 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $167K.
- Tower Research Capital (TRC) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 25 quarters.
- Tower Research Capital (TRC)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $614K in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.